Biểu đồ giá cổ phiếu UTHR
UTHR Dự đoán giá cổ phiếu
United Therapeutics Corp
$596.76
4.29%
$24.55
Khi đóng cửa: May 06, 16:00:00 GMT-4
$601.18
0.74%
$4.41
Phiên trước giờ: May 07, 06:31:15 GMT-4
Quay lại
United Therapeutics Corp (UTHR) Dự đoán giá cổ phiếu
Thống kê chính
Giá đóng cửa trước
$572.2
Giá mở cửa
$589.47
Phạm vi ngày
$575 - $609.35
Phạm vi 52 tuần
$272.12 - $607.89
Khối lượng
660.2K
Khối lượng trung bình
507.1K
Tỷ suất cổ tức
--
EPS (TTM)
27.90
Vốn hóa thị trường
$26.3B
UTHR là gì?
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 1,400 full-time employees. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
